Danaher has reported a net profit of $907m, or $1.22 per diluted share, for the second quarter ended 30 June 2024, an 18% decline compared to $1.1bn, or $1.49 per diluted share, for the corresponding period the previous year.
The life sciences company’s net profit for the second quarter of 2024 (Q2 2024) declined by 16% compared to $1.08bn or $1.45 diluted share for the first quarter of 2024 (Q1 2024).
Danaher reported net sales of $5.74bn for Q2 2024, a 2.8% decline compared to $5.91bn for the same quarter the previous year, and a 1% decrease compared to $5.79bn for Q1 2024.
The company reported operating expenses of $2.26bn for Q2 2024, a 5% rise compared to $2.15bn for the same quarter the previous year.
The firm reported a profit before tax of $1.08bn for Q2 2024, a 5% decrease compared to $1.14bn for the corresponding quarter in 2023.
Danaher president and CEO Rainer Blair said: “We had a good start to 2024, with our team delivering better-than-expected revenue, earnings, and cash flow.
“We were especially pleased to see improving order trends in our bioprocessing business and believe we continued to gain market share in our molecular diagnostics business at Cepheid.”
“Looking ahead, the powerful combination of our leading portfolio and our team’s commitment to executing with the Danaher Business System provides a strong foundation for differentiated long-term performance while helping to meaningfully improve human health.”
Danaher has reported a net profit of $1.99bn or $2.68 per diluted share for the six months ended 30 June 2024, a 21% decline compared to $2.53bn or $3.42 per diluted share for the same period the previous year.
The life sciences company reported net sales of $11.53bn for the first half of 2024 (H1 2024), a 2.8% decline compared to $11.86bn for the same period in 2023.
Danaher reported operating expenses of $4.52bn for H1 2024, a 5% rise compared to $4.3bn for the same period in the previous year.
The company reported a profit before tax of $2.35bn for H1 2024, an 11% decrease compared to $2.66bn for the corresponding period in 2023.
